Blog
RSS FeedPosted by Michael Wonder on 03 Apr 2019
Overprescribed: high cost isn’t America’s only drug problem
2 April 2019 - The pharmaceutical industry has followed a brilliant two-pronged strategy to maximize its profits: raise prices and ...
Posted by Michael Wonder on 03 Apr 2019
ICER issues final report on Spinraza and Zolgensma, provides policy recommendations related to pricing and coverage of treatments for spinal muscular atrophy
3 April 2019 - Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes ...
Posted by Michael Wonder on 03 Apr 2019
Trump retreats on health care after McConnell warns it won’t happen
2 April 2019 - President Trump backed off plans to introduce a Republican replacement for the Affordable Care Act after ...
Posted by Michael Wonder on 03 Apr 2019
Cigna’s Express Scripts PBM to cap insulin costs amid drug price scrutiny
3 April 2019 - Cigna and its Express Scripts pharmacy benefit management unit Wednesday said they are rolling out a ...
Posted by Michael Wonder on 03 Apr 2019
Gottlieb signs off with flair – and pledge of further drug price commentary
3 April 2019 - Highlights issues of insulin prices and competition. ...
Posted by Michael Wonder on 03 Apr 2019
FDA approves Asceniv, a novel intravenous immune globulin
1 April 2019 - Approved for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents (12 to ...
Posted by Michael Wonder on 03 Apr 2019
Evoke Pharma receives complete response letter and recommendations to address deficiencies from FDA for Gimoti NDA
2 April 2019 - Evoke Pharma today announced that it has received a complete response letter from the U.S. FDA ...
Posted by Michael Wonder on 03 Apr 2019
Institute for Clinical and Economic Review Appoints Dr. Pamela Bradt as Chief Scientific Officer
2 April 2019 - The Institute for Clinical and Economic Review has announced the appointment of Pamela Bradt as the organization's ...
Posted by Michael Wonder on 03 Apr 2019
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
2 April 2019 - Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim. ...
Posted by Michael Wonder on 02 Apr 2019
Doctors’ group cannot sue over cuts to Medicare drug reimbursements
2 April 2019 - A federal judge in Washington, D.C. has ruled that an association of oncologists cannot pursue a ...
Posted by Michael Wonder on 02 Apr 2019
Statement from FDA Commissioner on the agency’s continued efforts to bring competition to the insulin market to lower prices and expand access
2 April 2019 - Access to affordable insulin can be a matter of life and death for Americans with diabetes. ...
Posted by Michael Wonder on 02 Apr 2019
Price controls are never the answer
1 April 2019 - Senator Rick Scott has just doubled down on one of the Trump Administration’s unsound ideas. ...
Posted by Michael Wonder on 02 Apr 2019
When is the price of a drug unjust? The average lifetime earnings standard
1 April 2019 - The majority of Americans believe that lowering drug prices should be the top health care priority for ...
Posted by Michael Wonder on 01 Apr 2019
Ziopharm Oncology announces FDA fast track designation for Ad-RTS-hIL-12 plus veledimex for the treatment of recurrent glioblastoma
1 April 2019 - Ziopharm Oncology today announced that the U.S. FDA has granted fast track designation for its Controlled ...
Posted by Michael Wonder on 01 Apr 2019
Luye Pharma's Rykindo expected to be the first Chinese innovative drug to receive U.S. FDA approval
28 March 2019 - Luye Pharma Group has announced submission of a new drug application to the U.S. FDA for ...